非アルコール性脂肪肝疾患 (NAFLD) /代謝機能障害に関連した脂肪肝疾患 (MASLD) の循環器疾患リスクの体系的なレビューからの証拠
Nehal K Bhatt1, Yashasvi Agarwal2,3, Sanathanan Neelakantan Ramaswamy4
1Internal Medicine, Pramukhswami Medical College, Karamsad, IND.
Cureus
|September 5, 2025
まとめ
メタボリック機能障害に関連した脂肪酸性肝疾患 (MASLD) は,心臓血管疾患,特に進行性肝繊維症のリスクを大幅に増加させる. 早期の診断と標的型治療は この増加する健康上の懸念に対処するために不可欠です
科学分野:
- 心臓病と肝臓病
- メタボリックシンドロームの研究
- 公衆衛生と疫学
背景:
- 非アルコール性脂肪肝 (NAFLD),現在代謝機能障害に関連した脂肪性肝疾患 (MASLD) は,心血管疾患 (CVD) リスクに対する懸念が高まっている.
- MASLDのCVDへの独立した寄与は,代謝因子の混同と研究方法の多様性のために議論されています.
- 肝繊維症,代謝機能障害,心血管疾患との相互作用を理解することは,効果的なリスクの階層化に不可欠です.
研究 の 目的:
- MASLDと心血管疾患との関連に関する証拠を体系的に検討し,統合する.
- MASLD患者の心血管リスクに対する肝繊維症の重度と代謝機能障害の特定の影響を評価する.
- ランダム化試験の必要性を含む,既存の証拠の質を評価し,将来の研究のためのギャップを特定する.
主な方法:
- PRISMA 2020のガイドラインに従って,主要なデータベース (PubMed,ScienceDirect,Europe PMC,Cochrane Library) を2025年5月まで調査する.
- MASLD (画像検査,生検,またはFLI/FIB-4のような検証されたスコア) と心血管疾患 (MI,脳卒中,CVD死亡率,動脈硬化症) を評価する観察研究および試験を含める.
- 2人のレビュー者による独立したデータ抽出とバイアスのリスク評価 (NOS/Cochrane RoB2)
主要な成果:
- 21件の研究 (コホート18件,横断2件,RCT1件) が含まれており,サンプルサイズは最大950万件でした.
- MASLDは,心血管疾患のリスクの増加と一貫した,用量依存の関連性を示した (調整されたHRは1. 2から8. 0).
- 高度な線維症 (FIB-4>2. 67) はCVDリスクを4倍 (HR>4. 5),高い代謝負荷 (≥4の危険因子) はリスクを大幅に増幅した (HR=8. 04).
結論:
- MASLDは有害な心血管疾患の重要な独立リスク因子であり,肝繊維症の重症度や代謝併発症によってリスクが上昇します.
- MASLDは独立系因子として作用する一方で,代謝機能障害のマーカーとしても機能し,複雑な病理生理学を強調する.
- 非侵襲性線維症の評価をCVDリスクの分層化に統合することは支持されています.CVD予防のためのMASLD標的治療を試験するために,RCTを含むさらなる研究が必要です.
さらに関連する動画
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
4.0K
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
1.3K
関連する概念動画
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:17Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
01:23Assessment of the Cardiovascular System I: Subjective Data
465
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
465
01:26Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33